Bicara Therapeutics (BCAX) Competitors $11.75 -0.18 (-1.51%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$11.74 -0.01 (-0.04%) As of 07/25/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BCAX vs. RXRX, BHC, AGIO, ARWR, KNSA, TWST, CNTA, BEAM, CGON, and DNLIShould you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include Recursion Pharmaceuticals (RXRX), Bausch Health Cos (BHC), Agios Pharmaceuticals (AGIO), Arrowhead Pharmaceuticals (ARWR), Kiniksa Pharmaceuticals International (KNSA), Twist Bioscience (TWST), Centessa Pharmaceuticals (CNTA), Beam Therapeutics (BEAM), CG Oncology (CGON), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. Bicara Therapeutics vs. Its Competitors Recursion Pharmaceuticals Bausch Health Cos Agios Pharmaceuticals Arrowhead Pharmaceuticals Kiniksa Pharmaceuticals International Twist Bioscience Centessa Pharmaceuticals Beam Therapeutics CG Oncology Denali Therapeutics Bicara Therapeutics (NASDAQ:BCAX) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends. Do analysts recommend BCAX or RXRX? Bicara Therapeutics currently has a consensus price target of $31.86, suggesting a potential upside of 171.14%. Recursion Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 7.86%. Given Bicara Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Bicara Therapeutics is more favorable than Recursion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Recursion Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media favor BCAX or RXRX? In the previous week, Recursion Pharmaceuticals had 12 more articles in the media than Bicara Therapeutics. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 1 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 1.82 beat Recursion Pharmaceuticals' score of 0.45 indicating that Bicara Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Bicara Therapeutics Very Positive Recursion Pharmaceuticals Neutral Do institutionals and insiders hold more shares of BCAX or RXRX? 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 15.5% of Bicara Therapeutics shares are owned by insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is BCAX or RXRX more profitable? Bicara Therapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -961.32%. Bicara Therapeutics' return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A N/A N/A Recursion Pharmaceuticals -961.32%-74.70%-54.02% Which has stronger earnings and valuation, BCAX or RXRX? Bicara Therapeutics has higher earnings, but lower revenue than Recursion Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/A-$68MN/AN/ARecursion Pharmaceuticals$59.82M44.11-$463.66M-$1.77-3.67 SummaryBicara Therapeutics beats Recursion Pharmaceuticals on 10 of the 13 factors compared between the two stocks. Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition Export to ExcelMetricBicara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$650.61M$3.05B$5.70B$9.50BDividend YieldN/A2.37%4.58%4.00%P/E RatioN/A21.3228.3920.07Price / SalesN/A270.06427.4498.54Price / CashN/A42.7636.2258.56Price / Book1.308.378.675.88Net Income-$68M-$55.19M$3.25B$258.89M7 Day Performance7.50%5.86%4.30%3.70%1 Month Performance33.37%17.29%10.57%11.71%1 Year PerformanceN/A4.39%35.68%17.98% Bicara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara Therapeutics2.0858 of 5 stars$11.75-1.5%$31.86+171.1%N/A$650.61MN/A0.0032RXRXRecursion Pharmaceuticals0.7817 of 5 stars$6.40+9.6%$7.00+9.4%-19.4%$2.37B$58.84M-3.62400High Trading VolumeBHCBausch Health Cos3.0919 of 5 stars$6.34+0.4%$7.30+15.2%+15.1%$2.34B$9.63B-57.6020,700News CoverageUpcoming EarningsAGIOAgios Pharmaceuticals4.354 of 5 stars$39.92-0.2%$58.60+46.8%-17.5%$2.32B$36.50M3.55390Upcoming EarningsAnalyst ForecastARWRArrowhead Pharmaceuticals3.7806 of 5 stars$14.71-12.2%$43.71+197.2%-45.6%$2.31B$3.55M-10.51400News CoveragePositive NewsHigh Trading VolumeKNSAKiniksa Pharmaceuticals International3.4549 of 5 stars$28.42-2.1%$39.67+39.6%+1.6%$2.12B$423.24M-113.68220News CoverageTWSTTwist Bioscience4.3618 of 5 stars$34.77-1.1%$50.40+45.0%-37.4%$2.11B$312.97M-10.70990News CoverageCNTACentessa Pharmaceuticals3.3124 of 5 stars$16.06+2.4%$28.10+75.0%+49.8%$2.10B$6.85M-8.87200News CoverageInsider TradeBEAMBeam Therapeutics2.259 of 5 stars$21.03+1.3%$48.75+131.8%-32.5%$2.09B$63.52M-4.56510Analyst RevisionCGONCG Oncology2.6012 of 5 stars$26.90+0.6%$55.30+105.6%-20.9%$2.04B$1.14M-17.8161Positive NewsDNLIDenali Therapeutics4.2613 of 5 stars$13.83-1.2%$33.71+143.8%-43.3%$2.03BN/A-5.18430News CoverageUpcoming Earnings Related Companies and Tools Related Companies RXRX Competitors BHC Competitors AGIO Competitors ARWR Competitors KNSA Competitors TWST Competitors CNTA Competitors BEAM Competitors CGON Competitors DNLI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
